Daniel Chancellor

VP, Thought Leadership at Norstella      


Biopharma industry advisor with ~15 years of experience spanning drug discovery, market analysis, competitive intelligence, and strategic consulting. Currently delivering and overseeing thought leadership activities for Citeline and Evaluate, using proprietary, gold-standard datasets to communicate the opportunities and challenges facing the industry today. Regular contributor to Scrip and In Vivo newsletters, external commentator for leading business publications, including the WSJ, Reuters and The Economist, plus a frequent speaker and presenter at partnering conferences across the US, Europe and Japan.

Contributing Author   in
Bioeconomy & Society  

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Articles from Daniel

Obesity R&D: The Making of a $100 Billion Market

   635
Obesity R&D: The Making of a $100 Billion Market

Obesity has emerged as a focal point for drug development in recent years, driven by its growing prevalence across many countries. The burden on global healthcare systems is stark: in Britain, for instance, the NHS is estimated to spend around £6.5 billion annually on obesity treatments and related care. More importantly, the impact on patients is severe, with obesity contributing to debilitating comorbidities such as cardiovascular disease, cancer, and psychiatric disorders.